What is Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology firm dedicated to pioneering next-generation CAR-T therapies for enhanced cancer treatment. The company leverages proprietary platforms, including CoupledCAR and INSTACAR, to advance cellular immunotherapies, particularly for solid tumors. Its lead product candidate, GCC19CART, is designed to combat relapsed/refractory metastatic colorectal cancer. ICT is actively broadening its CAR-T candidate portfolio to target a wider array of solid tumors, utilizing the ARMORED CAR platform to amplify therapeutic efficacy. The company's core mission is to deliver innovative immunotherapy solutions to patients facing the challenges of cancer.
How much funding has Innovative Cellular Therapeutics raised?
Innovative Cellular Therapeutics has raised a total of $28.6M across 1 funding round:
Other Financing Round
$28.6M
Other Financing Round (2019): $28.6M with participation from LH Ventures
Key Investors in Innovative Cellular Therapeutics
LH Ventures
LH Ventures is an investor participating in the funding round. Further details on their investment focus are not publicly available.
What's next for Innovative Cellular Therapeutics?
The substantial enterprise-level capital infusion positions Innovative Cellular Therapeutics for significant growth and strategic expansion. This backing is expected to fuel further research and development, potentially accelerating clinical trials and the advancement of their CAR-T candidates targeting various solid tumors. The company's focus on proprietary platforms like CoupledCAR and INSTACAR suggests a strategy centered on technological differentiation and innovation in the highly competitive oncology landscape. Future developments will likely involve scaling manufacturing capabilities and forging strategic partnerships to broaden market access and bring their advanced immunotherapies to a wider patient population.
See full Innovative Cellular Therapeutics company page
